# Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

> **NCT06047834** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioCorRx Pharmaceuticals Inc** · enrollment: 24 (estimated)

## Conditions studied

- Opioid Withdrawal (Disorder)

## Interventions

- **DRUG:** Standard of Care with Lofexidine
- **OTHER:** Standard of Care without Lofexidine

## Key facts

- **NCT ID:** NCT06047834
- **Lead sponsor:** BioCorRx Pharmaceuticals Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-02
- **Primary completion:** 2025-05-11
- **Final completion:** 2026-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047834, "Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06047834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*